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Abstract This study evaluated the therapeutic potential of
masitinib, an oral tyrosine kinase inhibitor with activity
against c-Kit and platelet-derived growth factor receptors
(PDGFR), to reduce ischemic brain area and neurological
deficit. Using a well-established filament model of ischemic
stroke in rats, the responses to oral treatment with masitinib
alone or in combination with recombinant tissue plasminogen
activator (rt-PA) were compared to those after rt-PA (10 mg/kg
intravenously (i.v.)) monotherapy. In both cases, two doses of
masitinib were used—25 or 100 mg/kg, twice per day.
Ischemic brain area and the neurological deficit were assessed
using the triphenyltetrazolium chloride (TTC) method and
behavioral neurological tests, respectively. Masitinib, as a
single agent, reduced significantly the infarct size, as com-
pared with the stroke control group. Brain ischemic area
decreased from 9.14 to 4.36 % (25 mg/kg) or 2.60 %
(100 mg/kg). Moreover, a combined treatment of masitinib
with rt-PA produced a stronger effect than the one observed
after each of the compound alone. The size of the brain
ischemic area (rt-PA 1.67 %) was further reduced to 0.83 or
0.7 % at masitinib doses of 25 and 100 mg/kg, respectively.
Masitinib reduced significantly brain ischemia induced by
experimental stroke and potentiated the therapeutic effect of
rt-PA.
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Abbreviations




CNS Central nervous system
pMCAO Permanent middle cerebral artery occlusion
rt-PA Recombinant tissue plasminogen activator
SCG Stroke control group
TTC Triphenyltetrazolium chloride
Introduction
Despite stroke being the second leading cause of mortality
worldwide (Murray and Lopez 1977) and the third one of
premature mortality in developed countries (MacDonald et al.
2000), it remains largely without any significant therapeutic
strategies. Both ischemic and hemorrhagic strokes continue to
have very poor outcomes (Lukovits and Goddeau 2011).
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Evidence-based strategies for treatment of ischemic stroke
involve lowering blood pressure, reduction of cerebral edema,
temperature control, glucose regulation, and antiplatelet and
fibrinolytic treatments (Juvela et al. 1989; Kasner et al. 2002;
Diringer and Zazulia 2004; Bereczki et al. 2000; McCormick
et al. 2010). Recently, a new approach based upon neuropro-
tection has been proposed for the treatment of experimentally
induced ischemic stroke in mice and rats (Rehni et al. 2011;
Yuen et al. 2011).
Masitinib is an oral tyrosine kinase inhibitor that potently
targets a limited number of kinases including c-Kit and
platelet-derived growth factor receptors (PDGFR-α and
PDGFR-β). Both kinases are implicated in diseases with
inflammatory pathogenesis and various cancers (Dubreuil
et al. 2009). Stem cell factor (SCF), the ligand of the c-Kit
receptor, is a critical growth factor for mast cells. Masitinib
can also regulate the activation of mast cells through its
targeting Lyn and Fyn (Dubreuil et al. 2009). On the other
hand, mast cells are known for their important role in sustain-
ing the inflammatory network as they are one of the main
central nervous system (CNS) sources of cytokines and
chemokines (Stassen et al. 2002; Kinet 2007). Furthermore,
perivascular localized mast cells secrete numerous vasoactive
molecules and regulate blood-brain barrier (BBB) permeabil-
ity (Esposito et al. 2002; Zhuang et al. 1996).
Additionally, according to several papers ( Lindsberg et al.
2010; Strbian et al. 2006; Strbian et al. 2007; Strbian et al.
2009), mast cells may actively participate in the pathogenesis
of ischemic stroke.
Studies involving kinase inhibitor selectivity have shown
that masitinib is one of the most selective kinase inhibitor
under development (Anastassiadis et al. 2011). The drug’s
selectivity effectively determines its activity and safety pro-
file, i.e., potential for off-target effects and toxicity. Therefore,
masitinib appears to be a good candidate for adjuvant use with
current stroke management.
This study evaluated the therapeutic potential of masitinib
to reduce infarct size and neurological deficit induced by a
well-established intraluminal filament technique of ischemic
stroke in animals (Chu et al. 2008). On this model, the re-
sponses of low and high doses of the drug given alone or in
combination with recombinant tissue plasminogen activator
(rt-PA) were investigated and compared to standard thrombo-
lytic treatment (rt-PA).
Materials and methods
Study design and experimental animals
All experiments were performed on Wistar male rats,
weighing between 270 and 350 g. Older rats were used
because younger animals are more resistant to cerebral
ischemia (Zhang et al. 2005). They were kept in a 12-h day
and night cycle at room temperature, with access to water and
food ad libitum. Body temperature and weight were recorded
on a regular daily schedule. All procedures were carried out
according to guidelines outlined by the European Community
Council Directive of November 24, 1986 (86/609/EEC) and
by the local Ethical Committee.
Masitinib, provided by AB Science (Paris, France), was
administered orally as a suspension in distilled water by
stomach plumb, twice per day at either 25 or 100 mg/kg body
weight (b.w.). The first dose was applied 2 h poststroke and
every 12 h thereafter for 7 days. The thrombolytic agent, rt-
PA, was purchased from Boehringer Ingelheim, Germany. rt-
PAwas administered in slow intravenous (i.v.) infusion to the
tail vein 2 h post stroke. All measurements and procedures
took 7 days.
All experimental animals (N=56) were divided into seven
groups, with eight rats per group (Table 1). There were two
control groups: I—a basic control group (BCG)—without
stroke and treatment and II—a stroke control group
(SCG)—with stroke and treatment with saline solution. The
rest were five active treatment cohorts (III–VII), which com-
prised groups treated with rt-PA (10 mg/kg b.w.), masitinib
(25 or 100 mg/kg b.w.), and rt-PA+masitinib (25 or
100 mg/kg b.w.).
Induction of stroke
Induction of anesthesia was conducted in an anesthetic cham-
ber specifically adapted for small animal use by administra-
tion of 5.0 vol.% isoflurane (Abbot, USA) via Vaporizer
(Rothacher, Swiss). Anesthesia was maintained during the
surgical procedure with 3.8 vol.% isoflurane administered
through a T-piece circuit that was directly connected to a
close-fitting face mask. The animals were spontaneously ven-
tilated with 50 vol.% oxygen mixed with ambient room air.
During all procedures, the basic physiological parameters of
experimental animals were monitored and maintained within
physiological norms. Body temperature was kept at 36.5 to
37.5 °C. Permanent focal cerebral ischemia was experimen-
tally induced by occlusion of the left middle cerebral artery
(pMCAO) using the intraluminal filament technique (Longa
et al. 1989). Briefly, a 4-0 monofilament nylon suture
(Ethilon, UK), with heat-blunted tip, was inserted into the left
external carotid artery and advanced through the internal
carotid artery (at a depth of 15–17 mm) to occlude the origin
of the middle cerebral artery. However, this method was
modified by shortening of the suture (final length 2 cm).
This modification led to prolongation of rat’s survival and
enabled pharmacological manipulation within the period of
7 days (Lin et al. 2006). Following surgery, the animals were
allowed to recover spontaneous breathing and were kept under
standard conditions with free access to food and water.
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Behavioral tests
Animals were qualified for further study based on their
extent of neurological deficit. This was assessed using the
Bederson scale, 60 min after surgery (to determine success
of the occlusion), again 48 h post stroke, and finally im-
mediately prior to sacrifice (Bederson et al. 1986a, b;
Schaar et al. 2010). The test was performed at approxi-
mately the same time each morning and recorded by a
video camera. Rats were scored according to the following
scale: 0=no deficit; 1=failure to extend right forepaw; 2=
decreased resistance to lateral push or decreased grip of
right forelimb while tail pulled; and 3=spontaneous cir-
cling or walking to the contralateral side.
Two other behavioral tests, the cylinder test (assessing
spontaneous forelimb use) and the corner test (assessing
sensorimotor and postural asymmetries) were performed at
time-points of day 2 and 7 after stroke induction. In the
cylinder test, a rat is observed in a transparent Plexiglas
cylinder (20 cm diameter, 30 cm height). The number of
independent wall placements observed for the right fore-
limb, left forelimb, and both forelimbs simultaneously
were recorded by a video camera during 5 min (Schallert
and Woodlee 2005).
In the corner test, the rat was placed in a cage with one side
angled at 30° and recorded for 20 min. Normal subjects do not
exhibit a turning preference, but after ischemia, test subjects
have a turning preference to the non-impaired side. After the
rat approached the corner, it was returned to the starting
position. The number of left or right corner choices was
recorded and expressed as a percentage of all attempts
(Schallert and Woodlee 2005).
Physiological parameters
Physiological parameters as degree of consciousness is pre-
sented according to the listed scale below: 1=normal; 2=
mildly reduced; 3=severely reduced; and 4=comatose or
dead.
2,3,5-Triphenyltetrazolium chloride staining
The rats were sacrificed 7 days after pMCAO, their brains
immediately removed from the cranium and cooled to
4 °C. Five, 2-mm-thick coronal sections were made
starting from the frontal pole to the occipital one. The brain
slices were placed in 1 % solution of 2,3,5-triphenyltetra-
zolium chloride (TTC) (Sigma-Aldrich, Germany) in phos-
phate buffered saline (PBS, pH 7.4) and incubated in a dark
humid chamber (37 °C) for 30 min. Gentle stirring and
reversing of the plates ensured exposure of the slices to
uniform staining. The sections were then washed three
times with PBS and analyzed. In the intact brain, TTC is
reduced by succinate dehydrogenase to its red insoluble
form—formazan, while ischemic brain areas with inactive
enzymes are not stained and appear pale (Bederson et al.
1986a, b; Joshi et al. 2004). Subsequently, each slice was
photographed and the area of infarction, as well as the
whole brain section border, was outlined using an image-
analyzing program (AxioVision 4.8, Zeiss, Germany).
Statistics
The extent of brain damage was calculated as follows: the
area of ischemia for a given rat was expressed as a per-
centage of the total surface area of every individual rat
brain, taken as 100 %. Each brain was cut into five equal
sections. In each section, the damaged area was measured
and expressed as a percentage of the total section area.
Next, the mean value of the ischemic area for the whole
group (eight animals) was calculated and compared with
those obtained for the remaining experimental groups (cal-
culated using the same method).
To calculate statistical significance of differences in
ischemic area between experimental groups, the surface
area was additionally expressed in number of pixels.
Two-way ANOVA (Origin 8.5 and STATISTICA version
9.1) was used for calculation of statistical significance. A
difference between results with p values <0.05 was con-
sidered to be statistically significant.
Table 1 Experimental groups and procedures
Experimental group Procedure
Basic control group, BCG No stroke, no treatment
Stroke control group, SCG Stroke with 0.9 % NaCl 2 h poststroke
rt-PA monotherapy Stroke with rt-PA (10 mg/kg b.w.)
Masitinib (25 mg/kg) monotherapy Stroke with masitinib only (25 mg/kg b.w. twice per day)
Masitinib (25 mg/kg) rt-PA combination Stroke with rt-PA (10 mg/kg b.w.) plus masitinib (25 mg/kg b.w. twice per day)
Masitinib (100 mg/kg) monotherapy Stroke with masitinib only at 100 mg/kg b.w. (twice per day)
Masitinib (100 mg/kg) rt-PA combination Stroke with rt-PA (10 mg/kg b.w.) plus masitinib (100 mg/kg b.w. twice per day)
b.w. body weight, rt-PA recombinant tissue plasminogen activator
Naunyn-Schmiedeberg's Arch Pharmacol (2015) 388:79–86 81
Results
Infarct size evaluation with TTC staining in rats with stroke
and after treatment
The results obtained from all experimental groups are collect-
ed in Fig. 1 (Fig. 1a, b).
Representative images of coronal sections of each group
are shown in subpanel a. The selection of the section side
was determined by the distinctness of the ischemic area.
Subpanel b presents relative ischemic brain areas for the
treatment groups (calculated on the basis of coronal
sections).
Figure 1a column I presents brain structure and morpholo-
gy in the group of rats without stroke and any treatment
(BCG), whereas column II presents poststroke brains with
visible areas of ischemia (SCG) and clearly distinguished
edges between infracted and normal tissues. These changes
are further shown in a graphical presentation (subpanel b, bars
I and II). An average brain ischemic area of SCG exceeds 9 %.
Next images and bars (III–VII) of subpanels a and b, respec-
tively, represent data of treatment groups. Number III of the
image and bar reflects changes after standard fibrinolytic
therapy— rt-PA. The ischemic area here is reduced up to
1.67 % and is statistically significant in comparison to that
of SCG. Masitinib administered in the dose of 25 or
100 mg/kg b.w. reduced the infarct size to the values of 4.7
and 2.6 %, respectively (subpanel a images IV and VI; sub-
panel b bars IV and VI). In other words, there was a 49 %
reduction in the case of the smaller dose and 72 % of the
higher one. The most evident response is observed in the two
groups treated withmasitinib plus rt-PA (subpanel a, images V
and VII; subpanel B bars V and VII). Indeed, this improve-
ment of action (a reduction of brain ischemic area to 0.83 or
0.70 % for each of the dose of masitinib) was statistically
significant (p<0.05), as compared with rt-PA monotherapy.
Fig. 1 TTC images of brain
sections and relative infarct size in
experimental groups. a and b I—
basic control group (BCG); II—





(100 mg/kg) monotherapy; and
VII—masitinib (100 mg/kg)+rt-
PA. All data in (b) represent the
mean±S.E.M. **p<0.01,
statistically significant, as
compared to stroke control group
(SCG); #p<0.05, statistically
significant, as compared to rt-PA
monotherapy group
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Additionally, we have compared the volume and weight of
the brains from control andmasitinib-treated (with both doses)
groups and found no statistically significant differences be-
tween them (data not shown).
Behavioral observation
Generally, since the poststroke neurological deficit was rather
small, its expected impact on animals’ behavior could also be
only modest. This suggestion is confirmed by the results of the
behavioral tests. Moreover, the results obtained after both
doses of masitinib given alone or in combination with rt-PA
are a little bit ambiguous.
As compared to SCG, masitinib given alone reduced neu-
rological symptoms of stroke particularly if administered at a
dose of 100 mg/kg. The effect of the drug became visible in
the Benderson test after 2 and 7 days of stroke induction. On
the other hand, if combined with rt-PA, masitinib also in a
dose of 25 mg/kg produced an improvement in neurobehav-
ioral deficit which was mainly noticed in the corner (p<0.05)
and cylinder tests. Comparable results were obtained in all
tests with a dose of 100 mg/kg of masitinib plus rt-PA after 2
and 7 days. However, the differences did not reach statistical
significance (Table 2).
Physiological parameters
Masitinib induced sedation in all treated groups. The degree of
sedation was dose-dependent and became noticeable when
given alone or in combination with rt-PA. At the smaller dose
(25 mg/kg), masitinib producedmild sedation (second level of
the consciousness scale) and at the higher dose (100 mg/kg) a
severe sedation (third level of the consciousness scale).
A weight loss (ca. 30 g) was observed in all treatment
groups. Additionally, rats treated with masitinib (100 mg/kg)
plus rt-PA suffered from permanent diarrhea.
Discussion
Rat models of stroke are highly rated as inexpensive, repro-
ducible, and valuable because of significant similarity be-
tween human and rat brain circulation (MacLellan et al.
2010). Additionally, this species of rodents characterizes a
natural ability to develop cerebral collateral circulation lead-
ing to increase in angiogenesis in the postischemic region of
the brain (Lin et al. 2008). The experiments presented in this
study were performed on a model of stroke using an
intraluminal filament technique, in which occlusion of the
middle cerebral artery led to stroke with an average cerebral
ischemic area of about 9 % and mortality rate less than 10 %
during 7 days. This model provides an important advantage
over the embolic model of stroke in terms of mortality rate,
which by comparison is approximately 80 % during 2 days
with a corresponding brain ischemic area of more than 50 %
(Overgaard et al. 1992). Although neurological deficit was not
so expressive in the model used in this study, it permitted
evaluation of the effects of pharmacological intervention on
brain infarct size which would not be possible with an embolic
model of cerebral ischemia.
The results presented here showed that masitinib reduced
stroke-related brain infarct size on the model of stroke used in
Table 2 The results of different kinds of behavioral tests expressed in the number of appropriate movement (further explanation in the text)
Kind of behavioral
test
T [days] after inducing
stroke, when test was
performed
Legs Group I Group II Group III Group IV Group V Group VI Group VII
Benderson 2 0±0 0.125±0.33 0±0 0.625±0.67 0±0 0.375±0.48 0.375±0.48
7 0±0 0.125±0.33 0±0 0±0 0±0 0.25±0.66 0±0
Cylinder 2 L 7.625±4.41 1.625±1.22 1.375±1.73 3.125±2.93 2.375±1.58 1.25±1.3 0.5±1
R 6.125±2.67 1.5±1.12 2.25±1.3 2.75±1.2 3.125±2.52 0.5±0.5 1.375±1.49
B 1.25±1.3 0.375±0.7 0.25±0.43 0.625±0.86 0.625±0.7 0±0 0.625±0.7
7 L 3.375±2.12 2.625±2 2.25±0.22 1.625±1.11 0.75±1.64 0.625±1.11 0±0
R 5±3.46 2.5±2.65 4.75±4.41 1±1.12 0.625±0.7 0.5±0.71 0.125±0.33
B 0±0 0.25±0.43 0±0 0.25±0.43 0.125±0.33 0±0 0±0
Corner 2 L 4.125±1.16 0.75±0.82 0.25±0.43 0.5±0.7 1.125±1.05 1±1.32 0.25±0.43
R 5.875±1.16 0.375±0.48 1±0.5 0.875±1.36 1±1 1±0.86 0.125±0.33
7 L 4.625±0.99 1.875±2.52 0.25±0.43 1.375±1.99 1.5±1.58 0.5±0.7 0±0
R 4.875±1.05 1.625±2.17 0.375±0.69 1.75±1.29 0.875±0.92 0.25±0.43 0.375±0.48
The values are means±SEM calculated for each experimental group (n=8 for every group, no significant differences were detected)
T number of poststroke days after which the test was performed, L left leg, R right leg, B both legs
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this study. The most prominent neuroprotective effects of the
drug (evidenced by a reduced infarct size) became visible if it
was administered together with rt-PA. Moreover, these re-
sponses reached statistical significance, as compared to the
treatment with rt-PA alone (SCG). Thus, the results mentioned
above may suggest that masitinib given together with rt-PA
produced an additive therapeutic effect on poststroke rats. To
elucidate this additive action of both compounds, it should be
first carried out an analysis of the responses produced by each
of the single agent, i.e., by rt-PA or masitinib given alone.
Thrombolysis using rt-PA is the standard treatment for
acute ischemic stroke. However, there have been conflicting
data obtained concerning the effects of rt-PA after focal brain
ischemia. Even an aggravation of the injury has been noticed,
but mainly if rt-PA was used in mice (Wang et al. 1998).
However, the results of the experiments presented here, which
were carried out on rats, confirmed the therapeutic effect of
this drug. In relation to the existing data, the clinical problem
at hand is how to increase the overall efficacy of rt-PA and to
expand its therapeutic window, particularly by reducing or
eliminating the risk of hemorrhagic transformation (del
Zoppo and Hallenbeck 2000; Wang et al. 2004) which in-
creases with delayed administration of this agent.
In the light of the available research, it is difficult to put
forward a definite explanation of the neuroprotective effect of
masitinib. The therapeutic effect of the drug in question was
smaller than that produced by rt-PA. The latter observation
seems not to be surprising as there are several studies in which
usage of neuroprotectants without thrombolysis derived reper-
fusion was not very effective (Liu et al. 2010).
One of the possible mechanisms involved in this neuropro-
tection may be related to masitinib’s well-known inhibitory
action on tyrosine kinases, especially c-Kit and platelet-
derived growth factor receptors (e.g., PDGFR-β). The latter
seems to be important in the light of recent finding that
stimulation of PDGFR-β can disintegrate BBB in early phase
of brain ischemia (Shen et al. 2012). It has been shown that
both kinases are implicated in inflammatory diseases, as well
as various cancers, and PDGFR signaling regulates cerebro-
vascular permeability after stroke (Su et al. 2008). Thus, it
may be assumed that inhibition of PDGFR participated in the
neuroprotection of masitinib which was noticed in this study.
Similarly, a therapeutic potential of this drug has been dem-
onstrated in humans via proof-of-concept studies in such
neurological illnesses as Alzheimer’s disease (Piette et al.
2001) and multiple sclerosis (Vermersch et al. 2012).
Another mechanism which could explain the neuroprotec-
tive effect of masitinib is inhibition of mast cell activity in the
CNS or outside the brain. Different teams of researchers found
an increased presence of mast cells and their rapid degranula-
tion in association with morphologic changes of ischemic
brain injury (Lindsberg et al. 2010; Strbian et al. 2006). This
phenomenon led further to an augmentation of postischemic
BBB leakage and also contributed to hemorrhagic transfor-
mation (Tejima et al. 2007; Lindsberg et al. 2010).
Additionally, confirmation of mast cell contribution to stroke
was found on the transient MCAO model in rats in which
pharmacological mast cell stabilization with sodium
cromoglycate reduced the deleterious symptoms of stroke
(Strbian et al. 2009).
With respect to masitinib, the present study showed that
this drug reduced significantly (<0.05) the infarct territory in a
dose-dependent manner. This effect appeared despite its poor
BBB penetration. On the other hand, possible BBB leakage, a
characteristic feature of stroke condition, usually provides a
therapeutic opportunity for drugs that normally cannot cross
the BBB (Lin et al. 2006). However, lack of significant
differences in volume and weight of control and masitinib-
treated brains after the stroke in our experimental model
suggests negligible participation of this scenario (data not
shown).
Although we cannot provide further experimental data for
masitinib regarding direct brain effects related to neuronal
survival, affecting BBB or inflammation in stroke, we have
putative evidence from scientific literature that tyrosine kinase
inhibitors (including masitinib) poorly cross BBB, and even if
they can cross in a small amount they are quickly eliminated
from brain tissue by P-glycoprotein (ABCB1 and ABCG2)
(Lagas et al. 2009). Masitinib is known as a strong inhibitor of
PDGFR, but extracerebral inhibition of mast cell recruitment
is probably the most important component of preserving BBB
integr i ty and has highly s igni f icant impact on
neuroinflammatory cascade and activity of microglia in the
brain tissue (Skaper et al., 2012; Skaper et al. 2014).
The brief considerations concerning concepts of both rt-PA
and masitinib actions permit a better understanding and there-
by explanation of the additive interaction which was observed
here in the presented paper. The augmentation of rt-PA action
by masitinib may result from the fact that such combination
therapy targets a different pathway of ischemic cascade, acti-
vated during stroke, and masitinib preserves BBB against
disintegration in the presence of rt-PA. Similar suppositions
for explaining neuroprotective action of other agents in stroke
were presented by Strbian et al. (2009) or Liu et al. (2010).
Theoretically, the size of brain ischemic area should be
expressed by behavioral changes in poststroke animals.
However, such compatibility was not always observed in the
behavioral tests performed in this study. Perhaps, this incom-
patibility results from the limitations of the stroke model itself.
As it has already been mentioned, the size of ischemia here
was smaller than that in the classical pMCAO model. Thus,
the present results obtained from behavioral tests showed no
more than a trend towards reduced neurological symptoms of
stroke in rats receiving masitinib with or without rt-PA.
Statistically significant values were only observed if masitinib
(25 mg/kg) plus rt-PAwas investigated in the corner test.
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With respect to adverse drug reactions, masitinib produced
sedation which was especially visible after the dose of
100 mg/kg. Additionally, rats treated with this dose suffered
from permanent diarrhea.
To conclude, this study clearly demonstrated that masitinib
represents an attractive potential therapy of ischemic stroke.
Particularly promising seems to be the dose of 25 mg/kg, as it
decreased ischemic area by approximately 50 or 90 %, if the
drug was used alone or in combination with rt-PA, respective-
ly. These therapeutic actions were accompanied by manage-
able side effects. Further increase in the dose of masitinib
appears to be irrational because it led to more severe side
effects with lack of improvement in therapeutic action.
Summarizing, masitinib may be recommended as an ap-
propriate candidate for a neuroprotective strategy, especially
in the acute stage of stroke, the aim of which is to improve the
final outcome of the therapeutic intervention of ischemic
stroke with rt-PA and preserve BBB integrity. Therefore, the
drug deserves further clinical investigation and further re-
search to corroborate this study’s experimental observations
and better understand masitinib’s mechanisms of action in
stroke.
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